Abstract 551P
Background
The use of immune checkpoint inhibitors (ICI) has transformed the management of non-small cell lung cancer (NSCLC). With improved cancer outcomes have come increased auto-immune toxicities, which could affect any organ system. We investigated the incidence and outcomes of immune-related adverse events (irAE) in a large cohort of NSCLC patients.
Methods
Medical records from a metropolitan cancer centre in the AUstralian Registry and biObank of thoRAcic cancers (AURORA) registry were reviewed. Kaplan Meier analysis was used for survival estimates. Risk factors were tested using Fishers Exact test and logistic regression. False discovery rate of 5% was used to correct for multiple testing.
Results
Between 2013-2021, 449 patients received ICI. The median age was 65 years, 61% were male. Most (91%) had an ECOG of 0-1, 68% had metastatic disease at diagnosis, and 70% had adenocarcinoma. ICI was given as first line treatment in 47% of patients, and 22% had curative intent therapy. irAE were identified in 106 patients (24%). Most frequent was pneumonitis in 34 patients (incidence 7.6%); followed by colitis in 21 (4.5%), acute kidney injury in 19 (4.2%), thyroid disorders in 14 (3.1%), hepatitis in 12 (2.7%), skin toxicity in eight (1.8%), myositis in four (0.9%) and cardiac disorders and hypoadrenalism in three (0.7%) each. Toxicities noted twice included: arthropathy, hypoadrenalism, encephalitis, blood dyscrasias, diabetes, and ocular toxicities. Diabetes, gastritis and enteritis were identified in one patient each. Nineteen (4.2%) patients had two toxicities, one patient recorded three toxicities and one had four. No relationship was found between irAE and ICI combination therapy, smoking, age, performance status, or sex. The rate of pneumonitis was higher in those with airways disease than in those without (OR 14.81, 95% CI 6.64-33.59, P<0.01). Median overall survival in those with irAE was 18.7 months, versus 9.2 months in those without (HR 0.54, 95%CI 0.42-0.70, P=<0.01).
Conclusions
In a real word cohort, immune-related toxicities were similar to those reported in the literature. The development of irAE was associated with improved survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. M. Alexander: Financial Interests, Personal, Advisory Board: BMS/Pfizer. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract